Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00129766 · ClinicalTrials.gov registry record · Phase 3
Study of MEDI-524 (Motavizumab) for the Prophylaxis of Serious Respiratory Syncytial Virus (RSV) Disease in High-Risk Children
A Phase 3 study, sponsored by MedImmune.
- Completed
- Registry status
- Phase 3
- Development phase
- 6,635
- Enrollment target
NCT00129766 is a Phase 3 study that has completed, run by MedImmune. The registered enrollment target is 6,635 participants.
The verdict
NCT00129766, a Phase 3 study, has completed, sponsored by MedImmune.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 6,635 participants
- Enrollment target
Study Summary
The primary objective of this study was to compare the safety and efficacy of motavizumab to palivizumab when administered monthly by intramuscular (IM) injection for the reduction of the incidence of RSV hospitalization among children at high risk for serious RSV disease. A secondary objective was to compare the incidence of medically-attended lower respiratory infections (LRIs) between treatment groups.
Interventions
- BIOLOGICAL palivizumab
- BIOLOGICAL motavizumab (MEDI-524)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6,635 participants |
| Start Date | 2004-11 |
| Est. Completion | 2006-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00129766
The ClinicalTrials.gov registry entry for NCT00129766 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 6,635 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is MedImmune, which has 210 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which palivizumab is the first listed.
NCT00129766 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00129766 about?
NCT00129766 is a clinical study titled "Study of MEDI-524 (Motavizumab) for the Prophylaxis of Serious Respiratory Syncytial Virus (RSV) Disease in High-Risk Children". The primary objective of this study was to compare the safety and efficacy of motavizumab to palivizumab when administered monthly by intramuscular (IM) injection for the reduction of the incidence of RSV hospitalization among children at high risk for serious RSV disease. A secondary objective was ...
What is the current status of trial NCT00129766?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 6,635 participants. The study started on 2004-11. Estimated completion is 2006-05.
What interventions are being tested in trial NCT00129766?
The interventions under investigation include: palivizumab (BIOLOGICAL), motavizumab (MEDI-524) (BIOLOGICAL).
Who is sponsoring clinical trial NCT00129766?
This trial is sponsored by MedImmune, which has 210 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.